NASDAQ · Health care

Biodexa Pharmaceuticals Plc (BDRX)

We have not processed filings for Biodexa Pharmaceuticals Plc yet. This page fills in on its own once we have read them.

Price

$0.68

+0.15% on the day · September 25, 2026

52-week range $0.61 to $59.40

Market cap

$34.8M

What Biodexa Pharmaceuticals Plc does

Biodexa Pharmaceuticals Plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BDRX.

Latest SEC filings

What Biodexa Pharmaceuticals Plc has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 24, 2026
IPO registration (foreign issuer) F-1
September 15, 2026
Securities offering prospectus 424B3
September 15, 2026
Securities offering prospectus 424B3
September 15, 2026
Securities offering prospectus 424B3
September 15, 2026
Securities offering prospectus 424B3
September 15, 2026
Securities offering prospectus 424B3
September 15, 2026
Securities offering prospectus 424B3
September 15, 2026
Securities offering prospectus 424B3
September 15, 2026
Foreign issuer update 6-K
September 11, 2026
Securities offering prospectus 424B3

Recent insider filings (Forms 3, 4 and 144): 6, the latest on March 20, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about BDRX

What does Biodexa Pharmaceuticals Plc do?

Biodexa Pharmaceuticals Plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BDRX.

When did Biodexa Pharmaceuticals Plc last report?

Its newest filing of any kind is the iPO registration (foreign issuer) from September 24, 2026.

Similar companies

Follow BDRX

Get an email when Biodexa Pharmaceuticals Plc files with the SEC: results, executive changes, material agreements and annual reports.

Follow BDRX: get an email when it files

Where the numbers come from

Financial figures are the values Biodexa Pharmaceuticals Plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.